Adcirca
Product Images NDC 43353-070

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Adcirca (NDC 43353-070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 20mg (43353 0070 12)

Label for Adcirca Tadalafil 20 mg tablets, containing 12 tablets per package. The label includes the product name, active ingredient, strength, and count. It notes the drug is repackaged by Aphena Pharma Solutions - Tennessee, LLC, with mention of original manufacturing by Eli Lilly and Company, Indianapolis, IN. Includes storage instructions and RX only designation.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (Adcirca Tablets 01)

Chemical structure diagram showing the molecular structure of the active ingredient in ADCIRCA by Aphena Pharma Solutions - Tennessee, LLC. The structure depicts carbon rings, nitrogen atoms, and oxygen-containing functional groups.*

FDA Label Image

Figure 1 (Adcirca Tablets 05)

Line graph illustrating mean change from baseline (meters) over weeks in two groups: placebo (N=82) and ADCIRCA 40 mg (N=79). The ADCIRCA group shows increasing improvement over 16 weeks, with statistical significance indicated at weeks 4, 12, and 16. The placebo group shows minimal change across the same period.*

FDA Label Image

Figure 2 (Adcirca Tablets 06)

A forest plot illustrating the placebo-adjusted mean change in 6-minute walk distance (meters) with ADCIRCA 40 mg compared to placebo across various patient subgroups. The horizontal axis shows change values, with data points and 95% confidence intervals for subjects grouped by bosentan use, PAH etiology, baseline walk distance, gender, age, and WHO functional class.*

FDA Label Image

Figure 3 (Adcirca Tablets 07)

A Kaplan-Meier survival curve chart depicting the percentage of subjects without clinical worsening over time in days. The chart compares three groups: ADCIRCA 40 mg, ADCIRCA 20 mg, and placebo, showing their respective clinical outcomes during the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.